Study agents | Other agents | Disease | Dosage | Clinical trials | No Pts | Response | Reference |
---|---|---|---|---|---|---|---|
Alemtuzumab | Â | High risk | 30Â mg | Phase II | 93 | CR:2% | [19] |
ORR:33% | |||||||
Alemtuzumab | Dexamethasone | Untreated | 30Â mg | Phase II | 131 | CR:19/4/3% | [20] |
Relapsed | ORR:98/79/70% | ||||||
Refractory | |||||||
Alemtuzumab | Rituximab | High risk | 30Â mg | Phase I | 13 | CR:64% | [21] |
 | PGG beta glucan |  |  |  |  | ORR:100% |  |